Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 14, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 510,000 ordinary shares of 25 pence each.
- Purchase Price: 1,457.3923 pence per share.
- Treasury Holdings: 189,111,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,795,543,265 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 510,000 shares on August 14, 2006. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 510,000 share repurchase based on the disclosed price of 1,457.3923 pence.
- Confirm the updated total share count and Treasury holdings as of August 14, 2006.
- Review the original shareholder resolution from the May 17, 2006 Annual General Meeting to understand the scope of the buyback authority.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.